NCCN (Lynch syndrome)
Saturday, August 06, 2016
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome
Classic Li-Fraumeni syndrome criteria are as follows[2] :
-
A proband diagnosed with a sarcoma before age 45 years and
-
A first-degree relative with any cancer diagnosed before age 45 years and
-
Another first- or second-degree relative with any cancer diagnosed before age 45 years or a sarcoma diagnosed at any age
abstract:
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study - The Lancet Oncology
Background
Carriers of a germline TP53 pathogenic variant have a substantial lifetime risk of developing cancer. In 2011, we did a prospective observational study of members of families who chose to either undergo a comprehensive surveillance protocol for individuals with Li-Fraumeni syndrome or not. We sought to update our assessment of and modify the surveillance protocol, so in this study we report both longer follow-up of these patients and additional patients who underwent surveillance, as well as update the originally presented surveillance protocol.Methods
A clinical surveillance protocol using physical examination and frequent biochemical and imaging studies (consisting of whole-body MRI, brain MRI, breast MRI, mammography, abdominal and pelvic ultrasound, and colonoscopy) was introduced at three tertiary care centres in Canada and the USA on Jan 1, 2004, for carriers of TP53 pathogenic variants. After confirmation of TP53 mutation, participants either chose to undergo surveillance or chose not to undergo surveillance. Patients could cross over between groups at any time. The primary outcome measure was detection of asymptomatic tumours by surveillance investigations. The secondary outcome measure was 5 year overall survival established from a tumour diagnosed symptomatically (in the non-surveillance group) versus one diagnosed by surveillance. We completed survival analyses using an as-treated approach.Findings
Between Jan 1, 2004, and July 1, 2015, we identified 89 carriers of TP53 pathogenic variants in 39 unrelated families, of whom 40 (45%) agreed to surveillance and 49 (55%) declined surveillance. 19 (21%) patients crossed over from the non-surveillance to the surveillance group, giving a total of 59 (66%) individuals undergoing surveillance for a median of 32 months (IQR 12–87). 40 asymptomatic tumours have been detected in 19 (32%) of 59 patients who underwent surveillance. Two additional cancers were diagnosed between surveillance assessments (false negatives) and two biopsied lesions were non-neoplastic entities on pathological review (false positives). Among the 49 individuals who initially declined surveillance, 61 symptomatic tumours were diagnosed in 43 (88%) patients. 21 (49%) of the 43 individuals not on surveillance who developed cancer were alive compared with 16 (84%) of the 19 individuals undergoing surveillance who developed cancer (p=0·012) after a median follow-up of 46 months (IQR 22–72) for those not on surveillance and 38 months (12–86) for those on surveillance. 5 year overall survival was 88·8% in the surveillance group and 59·6% in the non-surveillance group.Interpretation
Our findings show that long-term compliance with a comprehensive surveillance protocol for early tumour detection in individuals with pathogenic TP53 variants is feasible and that early tumour detection through surveillance is associated with improved long-term survival. Incorporation of this approach into clinical management of these patients should be considered.Friday, August 05, 2016
Agenda: The Rivkin Center 11th Biennial Ovarian Cancer Research Symposium
Symposium Agenda | The Rivkin Center
Monday, September 12, 2016
Registration and Breakfast –
HUB Ballroom (Husky Union Building)
Welcome –
Kane Hall
Detection & Prevention of Ovarian Cancer
- –
Keynote Presentation
- –
Invited Speaker
- –
Abstract Session (2 presenters)
- –
Break
- –
Abstract Session Continued (6 presenters)
- –
Lunch with the Experts –
HUB Ballroom (Husky Union Building)
Mechanisms of Initiation & Progression of Ovarian Cancer
- –
Keynote Presentation
- –
Invited Speaker
- –
Abstract Session (2 presenters)
- –
Break
- –
Abstract Session Continued (6 presenters)
- –
Wrap Up
- –
Poster Session & Reception –
HUB Ballroom (Husky Union Building)
After Hours Events
Poster Session & Reception HUB Ballroom (Husky Union Building)
Tuesday, September 13, 2016
Registration and Breakfast –
HUB Ballroom (Husky Union Building)
Tumor Microenvironment & Models of Ovarian Cancer
Welcome –
Kane Hall
- –
Keynote Presentation
- –
Invited Speaker
- –
Abstract Session (2 presenters)
- –
Break
- –
Abstact Session Continued (6 presenters)
- –
Lunch with the Experts –
HUB Ballroom (Husky Union Building)
Novel Therapeutics for Ovarian Cancer
- –
Keynote Presentation
- –
Invited Speaker
- –
Abstract Session (2 presenters)
- –
Break
- –
Abstract Session Continued (6 presenters)
- –
Wrap Up
The 11th Biennial Ovarian Cancer Research Symposium is a CME Activity
jointly provided by the American Association for Cancer Research and the
Rivkin Center for Ovarian Cancer.
Are All Strong Opioids Equal for Chronic Cancer Pain? (note: high % non-responders)
medscape
print version
randomly assigned to receive oral morphine or oxycodone or transdermal fentanyl or buprenorphine for 28 days
Nevertheless, to our knowledge, this is the biggest randomized trial on opioid treatment in cancer pain.
Moreover, there were many non- or partial responders even though opioids are still widely considered the most effective tools for relieving cancer pain.
Study Design and Patients
This is a multicenter, randomized, open-label, active-controlled, four-arm, of superiority, phase IV clinical trial.Table 1. Main demographic and clinical characteristics of the patients at baseline
Discontinuation from the randomly given opioid mainly included unsuccessful pain relief or severe unmanageable toxicity; this occurred from 27% to 14.5%.
The variability in the response to opioids does not concern the actual analgesia as such, but the changes of therapy needed to maintain it.Conclusion: The main findings were the similarity in pain control, response rates and main adverse reactions among opioids. Changes in therapy schedules were notable over time. A considerable proportion of patients were nonresponders or poor responders.
recent page views by country (top 10) - Ovarian Cancer and Us (blog)
http://feeds.feedburner.com/blogspot/UnpPW
#1 United States
#2 Germany
| |
#3 South Korea
| |
#4 Romania
| |
#5 Russia
| |
#6 France
| |
#7 Canada
| |
#8 Portugal
| |
#9 China
| |
#10 Mauritius
|
Judge rules OMA ‘sneaky’ in bid to have doctors ratify deal with province (Ontario)
media
August 4, 2016
In a written decision that has the potential to undermine the credibility of the Ontario Medical Association, a Superior Court judge has concluded that the union’s executive abused its authority and was “unfair and confusing if not somewhat sneaky” in preparing a proxy vote on a new agreement with the province over doctor compensation.
In ordering the OMA to kill the proxy and send out a new one, Judge Paul Perell ruled that the original proxy was “unhelpful, unclear, unbalanced and unfair. It is a catalyst for a governance meltdown at the upcoming general meeting” scheduled for Aug. 14.
The judge’s written decision, released Thursday, contains hard language that raises questions about the OMA’s motives and tactics as it attempts to promote ratification — some say “ram through” — a complex agreement with Premier Kathleen Wynne’s Liberal government.....
Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer
abstract
OBJECTIVE:
This study aimed to assess the role and complications of extensive cytoreduction with PlasmaJet (Plasma Surgical, Roswell, Ga) in ovarian cancer with peritoneal carcinomatosis.
MATERIALS:
All patients undergoing primary, secondary, or interval debulking surgery for ovarian cancer and treated with PlasmaJet between October 2013 and February 2015 were analyzed.RESULTS:
Nineteen patients were enrolled. The median operative time was 270 minutes, median blood loss was 700 mL, and median length of stay was 9 days. In all patients, complete resection of all macroscopic disease was achieved.We used PlasmaJet to remove peritoneal carcinomatosis on the abdominal peritoneum, intestinal mesentery, bowel serosa, and diaphragmatic region. Overall, we treated 66 organs with PlasmaJet in our series. No bowel or urological fistulas were observed. According to the Clavien-Dindo classification, 13 adverse events were recorded at grade 2 or lesser. We observed only 1 grade 3 adverse event. No postoperative mortality was recorded.CONCLUSIONS:
In our series, the PlasmaJet seems to be an efficient device for tumor ablation or dissection to obtain complete resection of all macroscopic disease in patients with peritoneal carcinomatosis.Current South African clinical Practice in Debulking Surgery for Ovarian Cancer
abstract
CONCLUSIONS:
The progression of South African Gynaecological Oncologist towards more aggressive debulking surgery is following international trends, but many of the surgeons report a lack of experience in ultra-radical debulking surgery, especially in the upper abdomen.Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy
abstract:
Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy
OBJECTIVE:
Risk reducing salpingooophorectomy is recommended to women with a BReast CAncer susceptibility gene (BRCA) 1 or 2 germline mutation to reduce the risk of ovarian cancer. The incidence of unsuspected neoplasia varies in the literature. The purpose of this study was to identify the rate of unsuspected neoplasia in a high-risk Australian population, discuss their management, and assess the clinical outcome.METHOD:
This is a retrospective review of all women undergoing risk reductive salpingooophorectomy between January 2006 and December 2014. The medical, operative, and pathology results were reviewed. The specimens were assessed using the Sectioning and Extensively Examining the Fimbriated End protocol to the fallopian tube, and the ovary was also examined using 2 to 3 mm sectioning.RESULTS:
During the study period, 138 patients underwent risk-reducing salpingooophorectomy for a known BRCA 1 or 2 germline mutation or a high-risk personal or family history of ovarian cancer. Five patients with neoplasia were identified, 2 with invasive tubal carcinoma and 3 with serous tubal intraepithelial carcinoma (STIC), giving an overall incidence of 3.62%. Invasive tubal carcinoma occurred in 1 woman with a BRCA 1 mutation and 1 woman with a BRCA 2 mutation. The incidence of carcinoma in women with either a BRCA 1 or 2 germline mutation was subsequently 2.78%. STIC occurred in 2 women with a BRCA 1 germline mutation and 1 woman carrying a BRCA 2 germline mutation. The incidence of STIC in women with either a BRCA 1 or 2 germline mutation was subsequently 4.17%. Of the patients with STIC, all 3 remain disease free at an average follow-up period of 79.33 months.CONCLUSIONS:
In this retrospective review, we found the incidence of neoplasia within a high-risk Australian population undergoing risk-reducing bilateral salpingo-oophorectomy to be 3.62%. The incidence of STIC was 2.17%. During our follow-up period, all patients with STIC remained disease free.Thursday, August 04, 2016
Researcher Discusses Role for Maintenance Olaparib in Ovarian Cancer
Onclive
Wednesday, Aug 03, 2016
Olaparib (Lynparza)—which recently demonstrated an overall survival (OS) benefit as a maintenance therapy for relapsed patients with ovarian cancer—is an extremely exciting new agent, says Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom.
“The fact is, this drug really works,” said Gourley, an investigator on the phase II Study 19 trial of olaparib versus placebo as a maintenance therapy for patients with relapsed platinum-sensitive serous ovarian cancer.
“The study was designed to look at progression-free survival (PFS), and, unequivocally, it clearly showed that this drug improved PFS,” he added.
A third survival analysis of Study 19, presented at the 2016 ASCO Annual Meeting,1 demonstrated a median PFS of 8.4 months for patients receiving maintenance olaparib compared with 4.8 months for the control group (HR, 0.35; P <.0001). The difference in the BRCA mutation subgroup was even more pronounced, with a PFS of 11.2 months with olaparib and 4.3 months with placebo (HR, 0.18; P <.0001).
The analysis was performed with a cutoff of September 30, 2015, when the OS data were at 77% maturity. At this time, median OS in the entire study population (n = 265) was 29.8 months in the olaparib group and 27.8 months in the placebo group (HR, 0.73; 95% CI, 0.55–0.96; nominal P = .02483). In the BRCA mutation group (n = 136), where the data were at 70% maturity, median OS was 34.9 months for the olaparib group and 30.2 months for placebo (HR, 0.62; 95% CI, 0.41-0.94; nominal P = .02480).
OncLive spoke with Gourley to further explore the role of olaparib and discuss the impact the updated Study 19 data will have on the therapeutic landscape.
OncLive: Can you discuss what the significant findings were from this updated analysis?
Gourley: This is a study comparing the use of olaparib after chemotherapy to the use of placebo after chemotherapy. It has been presented several times before at ASCO, but this is an update. The reason why placebo is acceptable is because, as a standard, you don’t give anything after chemotherapy. It has already been shown that the olaparib improves the time until the cancer gets worse or comes back in patients with ovarian cancer.
We are now really looking at whether that affects survival. Data has suggested that the risk of death was 27% less with olaparib. If patients had a mutation in either the BRCA1 or BRCA2 gene, it seemed that the risk of death was 38% less if they received olaparib. That was quite exciting.
However, the main take-home message for me, as an oncologist, is that there seems to be a group of about 10% to 15% of patients who remain on the drug well into 5 years of treatment. For patients, with relapsed ovarian cancer, that is really something very new. We call these patients “super responders,” but we don’t really know what exactly makes someone a “super responder.” We are working on that, but that is one of the very exciting things to take away from this study.
Another important thing that came out of this study is that now, after several years of follow-up, we know a bit more about the safety of the drug, and it appears that there are no new issues that arrive from giving this drug for 5, 6, or 7 years. That is also reassuring.
What can the community oncologist take away from these findings?
The fact that there is potential improvement in OS really is something to aim for, but the only way to know if your patient should get this drug or not is to sequence them for BRCA1 or BRCA2.
Oncologists really need to be checking the BRCA1 and BRCA2 status of their patients, and then if they have a mutation, they should think about the potential of giving them olaparib— if they fit the license in that area.
Going forward, what role do you see olaparib playing in ovarian cancer?
The license, in both the United States and Europe, is for patients with BRCA1 and BRCA2 mutations. However, it is pretty clear from the Study 19 data that there are patients who don’t have a BRCA mutation and still benefit. What we have to do is to work out how to pick those patients out, in order to give them a chance of benefiting from this drug.
Olaparib is also being combined with other agents. People are also looking at the potential of using it without chemotherapy beforehand, and these studies are ongoing. There is nothing anywhere near license at this point, but combinations with anti-angiogenic agents, combinations with immunotherapies, and several other combinations are being investigated.
Is there any potential for the use of olaparib in an early setting?
We have seen what looks like an improvement in OS in this study, which was performed in the relapsed setting. The big question is, “When you move it into the first-line setting, and give it to patients who have just been diagnosed, can you improve their outcome?”
People don’t like to use the “cure” word, but we know that some patients are already cured with what we do. From what we’ve seen from Study 19, the big question in my mind is, “Can we cure more patients?” That is a massive question. There are trials addressing it that and I really look forward to seeing that data.
1. Ledermann JA, Harter P, Gourley C, et al.
Overall survival (OS) in patients (pts) with platinum-sensitive relapsed
serous ovarian cancer (PSR SOC) receiving olaparib maintenance
monotherapy: An interim analysis. J Clin Oncol 34, 2016 (suppl; abstr 5501).
CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvic disease for surgical planning
CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvic disease for surgical planning | Cancer Imaging | Full Text
Abstract
CT
of the abdomen and pelvis is the first line imaging modality for
staging, selecting treatment options and assessing disease response in
ovarian cancer. The staging CT provides disease distribution, disease
burden and is the imaging surrogate for surgico-pathological FIGO
staging. Optimal cyto-reductive surgery offers patients’ the best chance
for disease control or cure, but sub-optimal resection confers no
advantage over chemotherapy and adversely increases the risk of post
surgical complications. Although there is extensive literature comparing
performance of CT against laparoscopy and surgery, for the staging
abdominal and pelvic CT, there are currently no accepted guidelines for
interpretation or routinely used minimum data set templates for
reporting these complex CT scans often with extensive radiological
findings. This review provides a systematic approach for identifying the
important radiological findings and highlighting important sites of
disease within the abdomen and pelvis, which may alter or preclude
surgery at presentation or after adjuvant chemotherapy. The distribution
of sites and volume of disease can be used to categorize patients as
suitable, probably suitable or not suitable for optimal cyto-reductive
surgery. This categorization can potentially assist oncological surgeons
and oncologists as a semi objective assessment tool useful for
selecting patient treatment, streamlining multi disciplinary discussion
and improving the reproducibility and correlation of CT with surgical
findings. The review also highlights sites of disease and complications
of ovarian cancer which should be included as part of the radiological
report as these may require additional surgical input from non
gynaecological surgeons or influence treatment selection.
Background
CT
of the abdomen and pelvis is the standard imaging modality for
preoperative imaging staging at presentation and in distinguishing
between patients suitable for primary cyto-reductive surgery and
patients requiring neoadjuvant chemotherapy prior to surgery. Abdominal
and pelvic peritoneal disease is present in more than 70 % of the women
at the time of presentation. The optimal standard of care for patients
with ovarian cancer, is either primary cyto-reductive surgery or
adjuvant platinum based chemotherapy followed by cyto-reductive surgery [1].....
Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gyn cancer cells
open access: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells
In summary, we demonstrate for the first time that loss of ARID1A leads to accumulation of ROS and suggest that elesclomol may be used to target ARID1A-mutant gynecologic cancer cells.
The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
abstract: Cancer Investigation
The present systematic review summarizes current evidence regarding the mechanisms of action, the efficacy, and the adverse effects of tyrosine kinase inhibitors (TKIs) in ovarian cancer patients. Phase II and III clinical trials were sought in the PubMed database and in the Clinical Trials.gov registry through September 30, 2015. Seventy-five clinical trials regarding TKIs targeting mainly vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, and sarcoma tyrosine kinase (Src) were yielded. The most promising results were noted with cediranib, nintedanib, and pazopanib. However, drawing universal conclusions about the potential integration of TKIs in ovarian cancer therapy remains elusive. Furthermore, emerging challenges and directions for the future research are critically discussed.
Association between dietary nitrate and nitrite intake and site specific cancer risk: evidence from observational studies
What has nitrates in it?
Manufacturers add nitrates and nitrites to foods such as cured sandwich meats, bacon, salami
or sausages to give them color and to prolong their shelf life. When
added to processed foods in this way, both nitrates and nitrites can
form nitrosamines in the body, which can increase your risk of developing cancer.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
open access (pdf): Association between dietary nitrate and nitrite intake and sitespecific cancer risk: evidence from observational studies | Xie | Oncotarget
No significant associations were found between dietary nitrate/nitrite and cancers of the breast, bladder, colorectal, esophagus, renal cell, non-Hodgkin lymphoma, ovarian, and pancreas. The present meta-analysis provided modest evidence that positive associations of dietary nitrate and negative associations of dietary nitrite with certain cancers.
The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 1: Olaparib
open access:
The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 1: Olaparib
Clinical Advances in Hematology & Oncology
Volume 14, Issue 8, August 2016
Conclusions and Future Directions
The introduction of olaparib and other PARP inhibitors represents one of the most promising genotype-directed therapies, which are destined to change the management of BRCA-associated ovarian cancer. However, a number of challenges still remain.
Firstly, it is uncertain how olaparib should be incorporated into the clinical management of both BRCA1/2-associated and sporadic ovarian cancers. It has yet to be established whether olaparib should be introduced before or after platinum therapy, in the first-line or relapsed setting, or as maintenance therapy. Secondly, it is not clear whether, as maintenance therapy, additional benefit would be obtained if olaparib (or indeed, another PARP inhibitor) maintenance were to be reinstituted at each chemotherapy-induced remission. Another challenge is determining whether combination therapy is superior to single-agent olaparib use. Owing to overlapping toxicities, particularly myelosuppression, work is required to define the optimal schedules for the combination of chemotherapy and olaparib. Furthermore, it is unclear where combination treatment with vascular endothelial growth factor and other signaling inhibitors is best employed. In addition, the role of olaparib in platinum-resistant disease requires clarity. Finally, it is not yet known whether clinical differences exist between PARP inhibitors in terms of efficacy and toxicity, or indeed whether there is a role for rechallenge with a different PARP inhibitor following progression on another.
Several phase 3 trials are underway to address many of the above questions, and it is hoped that the use of olaparib and other PARP inhibitors can be optimized to maximize PFS—and ultimately, OS—for patients with ovarian cancer.
Wednesday, August 03, 2016
First comprehensive list of cancer blood biomarkers researched in last 5 years (in research)
Medical News
The work was carried out on behalf of the Early Cancer Detection Consortium, a group of nearly 40 organisations, including universities, hospitals and commercial companies.
The next step will be to look in detail at the research behind each biomarker, to check that it is robust and that the biomarker could feasibly be used as part of a screening test. Biomarkers will also be grouped by cancer type at this stage. The validated biomarkers will then be put through a clinical study, using samples from cancer patients and healthy controls, to check how effectively they identify the presence of cancer.Article: Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review, Lesley Uttley, Becky L. Whiteman, Helen Buckley Woods, Susan Harnan, Sian Taylor Philips, Ian A. Cree, EBioMedicine, doi: 10.1016/j.ebiom.2016.07.004, published online 6 July 2016.
Electronic Release of Pathology and Radiology Results to Patients: Opinions and Experiences of Oncologists
abstract
Purpose: There is an
emerging standard to provide patients rapid electronic access to
elements of their medical records. Although
surveys of patients generally support it, this
practice is controversial among oncologists, because few empiric data
are available
for scenarios of potentially life-threatening
conditions like cancer. We report the views of oncologists about patient
electronic
access to radiology and pathology results that
could potentially indicate disease progression.
Methods: Four months
before oncologists were surveyed, final results of radiology/pathology
reports were routinely made available
to patients online through a secure portal after
a 7-day, hold to provide clinicians time to review and communicate
results
with the patients. Mixed methods were used to
assess physician attitudes and experiences toward this change.
Results: One hundred
twenty-nine oncologists were surveyed, and 82 (64%) responded. A small
majority (54%) responded that the release
of reports was somewhat or very beneficial for
patients who received normal radiology/pathology results before
discussion
with a physician, but 87% said it was somewhat
or very harmful for patients to receive abnormal results before
discussion.
Forty-nine percent reported that release of
reports had a somewhat or very negative impact on communication with
their patients.
Conclusion: Almost
half of oncologists reported that sharing digital radiology and
pathology records had a negative impact on their communication
with patients. Patient surveys in similar cancer
populations would complement the physician perspective. Efforts are
needed
to improve consensus among oncologists and
patients on how to best communicate such results in a timely fashion.
"ovarian neoplasms" - PubMed - recent articles (some abstracts/some open access)
"ovarian neoplasms"
Items: 1 to 20 of 68828
1.
Burnik Papler T, Frković Grazio S, Kobal B.
J Ovarian Res. 2016 Jul 30;9(1):46. doi: 10.1186/s13048-016-0257-4.
- PMID:
- 27473538
2.
Lee HM, So KA, Kim MK, Lee YK, Lee IH, Kim TJ, Lee KH.
Obstet Gynecol Sci. 2016 Jul;59(4):333-6. doi: 10.5468/ogs.2016.59.4.333. Epub 2016 Jul 13.
- PMID:
- 27462604
3.
Jin JH, Kim HJ, Kim CY, Kim YH, Ju W, Kim SC.
Obstet Gynecol Sci. 2016 Jul;59(4):279-85. doi: 10.5468/ogs.2016.59.4.279. Epub 2016 Jul 13.
- PMID:
- 27462594
4.
Chung H, Kim YH, Kwon M, Shin SJ, Kwon SH, Cha SD, Cho CH.
Obstet Gynecol Sci. 2016 Jul;59(4):261-8. doi: 10.5468/ogs.2016.59.4.261. Epub 2016 Jul 13.
- PMID:
- 27462592
5.
Kim B, Kim HS, Kim S, Haegeman G, Tsang BK, Dhanasekaran DN, Song YS.
Cancer Res Treat. 2016 Jul 18. doi: 10.4143/crt.2016.175. [Epub ahead of print]
- PMID:
- 27456942
repeat: Adult BMI and risk of ovarian cancer by subtype (that's a No)
open access
CONCLUSIONS:
Our data suggest that higher BMI increases risk of non-HGSC, but not the more common and aggressive HGSC subtype, confirming the observational evidence.Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA
Open access:
Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA
This study highlights the variability in methylation level at different CpG sites close to the BRCA1 transcription start site. Methylation levels in tumour are generally greater than those in blood, and methylation at most sites (apart from +27) increases in triple negative tumours and those with a high BRCA1-like features scores. Analysis of BRCA1 promoter methylation may contribute to strategies for the identification of women who may benefit from PARP inhibition or other targeted therapies, as has occurred in BRCA associated ovarian cancer [54].
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1/2 Mutation Carriers
open access
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan
Open access
In conclusion, Strategy 1 (IHC test followed by BRAF test) evaluated in our study has been found to be cost-effective relative to the Referent strategy. This is the first cost-effectiveness analysis for evaluating different genetic testing strategies for LS in Taiwan. As such, the results will be informative for the NHI when considering offering screening for LS in patients newly diagnosed with CRC.
Case Report: Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration
Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer
abstract:
Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer: A Single-Institution Experience with 244 Patients | Radiology
Purpose
Materials and Methods
Tuesday, August 02, 2016
BRCA: List Results - ClinicalTrials.gov
Search of: brca | Open Studies | Exclude Unknown
120 studies found for:
brca | Open Studies | Exclude Unknown
Lynch Syndrome - List Results - ClinicalTrials.gov
Search of: lynch syndrome | Open Studies | Exclude Unknown
28 studies found for:
lynch syndrome | Open Studies | Exclude Unknown
Subscribe to:
Comments
(
Atom
)
